LuciFezo 45mg, Fezolinetant Tablets

LuciFezo 45mg contains Fezolinetant, a novel nonhormonal treatment option developed for managing moderate to severe vasomotor symptoms (VMS) associated with menopause, such as hot flashes and night sweats. It is a significant advancement in menopausal care for women who seek non-estrogen therapy due to personal preference or contraindications.

What is LuciFezo 45mg?

Fezolinetant, a selective neurokinin-3 receptor (NK3R) antagonist, is used in the formulation of the prescription drug LuciFezo 45mg. It is designed to alleviate menopausal symptoms by regulating the brain’s temperature control center without involving hormonal pathways. This makes it suitable for women who cannot or prefer not to use hormone replacement therapy (HRT).

How it Works / Mechanism of Action

Fezolinetant acts by blocking neurokinin B (NKB) from binding to NK3 receptors in the hypothalamus—a brain region that controls temperature regulation. During menopause, declining estrogen levels lead to an overactive NKB signaling pathway, causing the hypothalamus to misinterpret body temperature, resulting in hot flashes and night sweats.

By selectively antagonizing NK3 receptors, Fezolinetant modulates the activity of KNDy neurons (which release kisspeptin, neurokinin B, and dynorphin) and stabilizes thermoregulatory function. This reduces the frequency and severity of vasomotor symptoms without the use of estrogen.

How to Use / Indications

LuciFezo 45mg is indicated for:

• treatment for women experiencing moderate to severe vasomotor symptoms (VMS) related to menopause.

It is especially valuable for:

• Women with contraindications to hormonal therapy
• Women at risk of estrogen-sensitive cancers
• Women who have severe night sweats or hot flashes

How to Take / Dosage

• Recommended Dose: One tablet of LuciFezo 45mg once daily, taken orally with or without food.
• To keep blood levels steady, the tablet should be taken at the same time every day.
• Swallow the tablet whole with a glass of water; do not crush, chew, or split.

Other Dosage and Special Considerations

Currently, Fezolinetant is available primarily in the 45mg dosage.

No dose adjustment is typically needed for:

• Mild to moderate renal impairment
• Mild hepatic impairment

Not recommended in:

• Severe renal or hepatic impairment
• Patients with end-stage liver disease
• Always consult your healthcare provider before adjusting or stopping the dose.

Side Effects

Fezolinetant is generally well tolerated, but like all medications, it may cause side effects. Common and rare adverse reactions include:

Common side effects:

• Headache
• Abdominal pain
• Diarrhea
• Insomnia
• Fatigue

Less common but serious side effects:

• Elevated liver enzymes (transaminases)
• Hepatotoxicity (rare but requires monitoring)
• Allergic reactions (rash, itching, swelling)
• Patients are advised to undergo liver function tests prior to initiation and periodically thereafter.

Storage

• Store LuciFezo 45mg at room temperature (15°C to 30°C).
• Keep the medication in its original packaging, away from moisture and light.
• Do not use if the packaging is damaged or after the expiration date.
• Keep out of reach of children and pets.

Benefits

• Women who are unable or unwilling to take estrogen can benefit from nonhormonal treatment.
• Rapid symptom relief: Significant reduction in VMS seen within 1 week of starting treatment.
• Well-tolerated with a favorable safety profile in long-term clinical trials.
• No impact on breast or endometrial tissue, which may reduce cancer risks associated with hormonal therapies.
• Improved quality of life, better sleep, and enhanced daily functioning.

Prescription

• LuciFezo 45mg is a prescription-only medication. It should be:
• Prescribed by a qualified healthcare professional (e.g., gynecologist, endocrinologist).
• Not used without prior medical consultation, especially in women with liver conditions, history of hormone-sensitive cancer, or on medications affecting liver enzymes.
• Liver function monitoring is crucial both prior to and during treatment.

Drug Interactions

Fezolinetant is primarily metabolized by the CYP1A2 enzyme in the liver. Interactions can occur with:

Drugs that may increase Fezolinetant levels (risk of side effects):

• CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin)

Drugs that may decrease effectiveness:

• CYP1A2 inducers (e.g., smoking, rifampin)

Avoid using with:

• Strong CYP1A2 inhibitors unless benefits outweigh risks
• Drugs with known hepatotoxicity without close monitoring
• Always inform your doctor about any other medications, supplements, or herbal products you are taking.

FAQs

Is LuciFezo 45mg a hormonal drug?

No, it is a nonhormonal treatment for menopausal symptoms.

How long does it take to work?

Many women experience relief from symptoms within 1 week of use.

Can it be used with HRT?

Typically not used in combination with hormone therapy. Always consult your doctor.

Conclusion

LuciFezo 45mg (Fezolinetant) represents a breakthrough in managing menopausal vasomotor symptoms, especially for women who prefer or require non-estrogen therapy. It addresses a major quality-of-life issue for menopausal women using a novel mechanism that targets central thermoregulation without affecting hormone levels.

With its favorable efficacy and safety profile, LuciFezo provides a much-needed option in the menopausal care landscape. However, proper medical supervision, awareness of possible liver-related side effects, and attention to drug interactions are essential for safe and effective use.